A heparin-rosuvastatin-loaded P(LLA-CL) nanofiber-covered stent inhibits inflammatory smooth-muscle cell viability to reduce in-stent stenosis and thrombosis.
Animals
Apoptosis
/ drug effects
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Constriction, Pathologic
/ drug therapy
Cytokines
/ metabolism
Heparin
/ pharmacology
Intracranial Aneurysm
/ therapy
Male
Mice
Muscles
/ drug effects
Nanofibers
/ chemistry
Polyesters
/ chemistry
Rabbits
Rosuvastatin Calcium
/ pharmacology
Stents
Thrombosis
/ drug therapy
Intracranial aneurysm
Late thrombosis
Long-term arterial stenosis
Nanofiber-covered stent
Rosuvastatin
Journal
Journal of nanobiotechnology
ISSN: 1477-3155
Titre abrégé: J Nanobiotechnology
Pays: England
ID NLM: 101152208
Informations de publication
Date de publication:
29 Apr 2021
29 Apr 2021
Historique:
received:
19
02
2021
accepted:
20
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
26
10
2021
Statut:
epublish
Résumé
An endovascular covered-stent has unique advantages in treating complex intracranial aneurysms; however, in-stent stenosis and late thrombosis have become the main factors affecting the efficacy of covered-stent treatment. Smooth-muscle-cell phenotypic modulation plays an important role in late in-stent stenosis and thrombosis. Here, we determined the efficacy of using covered stents loaded with drugs to inhibit smooth-muscle-cell phenotypic modulation and potentially lower the incidence of long-term complications. Nanofiber-covered stents were prepared using coaxial electrospinning, with the core solution prepared with 15% heparin and 20 µM rosuvastatin solution (400: 100 µL), and the shell solution prepared with 120 mg/mL hexafluoroisopropanol. We established a rabbit carotid-artery aneurysm model, which was treated with covered stents. Angiography and histology were performed to evaluate the therapeutic efficacy and incidence rate of in-stent stenosis and thrombosis. Phenotype, function, and inflammatory factors of smooth-muscle cells were studied to explore the mechanism of rosuvastatin action in smooth-muscle cells. Heparin-rosuvastatin-loaded nanofiber scaffold mats inhibited the proliferation of synthetic smooth-muscle cells, and the nanofiber-covered stent effectively treated aneurysms in the absence of notable in-stent stenosis. Additionally, in vitro experiments showed that rosuvastatin inhibited the smooth-muscle-cell phenotypic modulation of platelet-derived growth factor-BB induction and decreased synthetic smooth-muscle-cell viability, as well as secretion of inflammatory cytokines. Rosuvastatin inhibited the abnormal proliferation of synthetic smooth-muscle cells, and heparin-rosuvastatin-loaded covered stents reduced the incidence of stenosis and late thrombosis, thereby improving the healing rates of stents used for aneurysm treatment.
Sections du résumé
BACKGROUND
BACKGROUND
An endovascular covered-stent has unique advantages in treating complex intracranial aneurysms; however, in-stent stenosis and late thrombosis have become the main factors affecting the efficacy of covered-stent treatment. Smooth-muscle-cell phenotypic modulation plays an important role in late in-stent stenosis and thrombosis. Here, we determined the efficacy of using covered stents loaded with drugs to inhibit smooth-muscle-cell phenotypic modulation and potentially lower the incidence of long-term complications.
METHODS
METHODS
Nanofiber-covered stents were prepared using coaxial electrospinning, with the core solution prepared with 15% heparin and 20 µM rosuvastatin solution (400: 100 µL), and the shell solution prepared with 120 mg/mL hexafluoroisopropanol. We established a rabbit carotid-artery aneurysm model, which was treated with covered stents. Angiography and histology were performed to evaluate the therapeutic efficacy and incidence rate of in-stent stenosis and thrombosis. Phenotype, function, and inflammatory factors of smooth-muscle cells were studied to explore the mechanism of rosuvastatin action in smooth-muscle cells.
RESULT
RESULTS
Heparin-rosuvastatin-loaded nanofiber scaffold mats inhibited the proliferation of synthetic smooth-muscle cells, and the nanofiber-covered stent effectively treated aneurysms in the absence of notable in-stent stenosis. Additionally, in vitro experiments showed that rosuvastatin inhibited the smooth-muscle-cell phenotypic modulation of platelet-derived growth factor-BB induction and decreased synthetic smooth-muscle-cell viability, as well as secretion of inflammatory cytokines.
CONCLUSION
CONCLUSIONS
Rosuvastatin inhibited the abnormal proliferation of synthetic smooth-muscle cells, and heparin-rosuvastatin-loaded covered stents reduced the incidence of stenosis and late thrombosis, thereby improving the healing rates of stents used for aneurysm treatment.
Identifiants
pubmed: 33926468
doi: 10.1186/s12951-021-00867-8
pii: 10.1186/s12951-021-00867-8
pmc: PMC8086342
doi:
Substances chimiques
Cytokines
0
Polyesters
0
poly(lactic acid-co-epsilon-caprolactone)
0
Rosuvastatin Calcium
83MVU38M7Q
Heparin
9005-49-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
123Subventions
Organisme : The Outstanding Academic Leaders Program of Shanghai Municipal Commission of Health and Family Planning
ID : 2017BR006
Organisme : National Natural Science Foundation of China
ID : 81571102
Organisme : National Natural Science Foundation of China
ID : 81870911
Organisme : National Natural Science Foundation of China
ID : 81801148
Organisme : Shanghai Municipal Science and Technology Major Project
ID : 2018SHZDZX01
Organisme : CAMS Innovation Fund for Medical Sciences
ID : 2019-I2M-5-008
Organisme : Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy (CN)
ID : SHDC2020CR2034B
Organisme : Clinical Research Plan of SHDC
ID : SHDC2020CR4033
Références
Biomaterials. 2007 Dec;28(34):5009-27
pubmed: 17688939
Molecules. 2019 Feb 26;24(5):
pubmed: 30813599
Atherosclerosis. 1999 Jun;144(2):335-42
pubmed: 10407494
Cardiovasc Radiat Med. 1999 Jan-Mar;1(1):48-54
pubmed: 11272356
J Biomed Mater Res A. 2015 May;103(5):1784-97
pubmed: 25196988
Biomaterials. 2003 Oct;24(23):4181-90
pubmed: 12853248
Neurosurg Rev. 2007 Jul;30(3):177-80; discussion 180
pubmed: 17508225
Arterioscler Thromb Vasc Biol. 2008 Nov;28(11):1960-6
pubmed: 18688017
Acta Biomater. 2017 Sep 15;60:3-22
pubmed: 28716610
Eur Radiol. 2013 Jan;23(1):287-97
pubmed: 22782569
Eur Heart J. 2008 Feb;29(3):402-12
pubmed: 18212388
J Biomech. 2005 Jun;38(6):1221-7
pubmed: 15863106
Platelets. 2016 Jul;27(5):410-9
pubmed: 26765134
J Biomed Mater Res A. 2011 Jun 1;97(3):339-47
pubmed: 21465642
Lancet Neurol. 2014 Jan;13(1):59-66
pubmed: 24290159
Circulation. 1997 Mar 18;95(6):1549-53
pubmed: 9118524
FASEB J. 2005 May;19(7):804-6
pubmed: 15728660
World Neurosurg. 2019 Mar;123:e194-e201
pubmed: 30476668
Nat Rev Neurol. 2016 Dec;12(12):699-713
pubmed: 27808265
J Am Coll Cardiol. 2010 Apr 13;55(15):1553-65
pubmed: 20378071
J Neurosurg. 1992 Oct;77(4):515-24
pubmed: 1527608
AJNR Am J Neuroradiol. 2007 Sep;28(8):1579-85
pubmed: 17846216
J Cardiovasc Transl Res. 2014 Jun;7(4):413-25
pubmed: 24800874
ACS Appl Mater Interfaces. 2018 Dec 5;10(48):41012-41018
pubmed: 30403126
Acta Neurochir (Wien). 2004 Jul;146(7):705-11
pubmed: 15197614
Lancet. 2003 Jul 12;362(9378):103-10
pubmed: 12867109
Adv Healthc Mater. 2021 Feb;10(3):e2000604
pubmed: 33300246
Physiol Rev. 1979 Jan;59(1):1-61
pubmed: 108688
Am J Cardiol. 1988 Oct 1;62(10 Pt 2):3F-24F
pubmed: 2972185
Neurosurgery. 2009 Apr;64(4):632-42; discussion 642-3; quiz N6
pubmed: 19349825
Atherosclerosis. 1995 Dec;118(2):213-21
pubmed: 8770315
Biomed Pharmacother. 2018 Jul;103:844-850
pubmed: 29710500
Rev Esp Cardiol (Engl Ed). 2015 Dec;68(12):1118-24
pubmed: 26206247
PLoS One. 2015 Apr 15;10(4):e0122577
pubmed: 25874930
J Biomed Mater Res A. 2009 Jul;90(1):205-16
pubmed: 18491396
Clin Exp Immunol. 1986 May;64(2):261-8
pubmed: 3527502
Lancet. 2002 Oct 26;360(9342):1267-74
pubmed: 12414200
J Am Coll Cardiol. 2004 Aug 18;44(4):733-9
pubmed: 15312851
Lancet. 2005 Sep 3-9;366(9488):809-17
pubmed: 16139655
Int Heart J. 2019 Sep 27;60(5):1154-1160
pubmed: 31484855
Arterioscler Thromb Vasc Biol. 2002 Jul 1;22(7):1093-9
pubmed: 12117722
Lancet Neurol. 2009 Jul;8(7):635-42
pubmed: 19501022
Circulation. 2003 Jul 8;108(1):37-42
pubmed: 12821546
AJNR Am J Neuroradiol. 2014 Dec;35(12):2326-33
pubmed: 24722307
Vascul Pharmacol. 2015 Jul;70:8-14
pubmed: 25737404
J Control Release. 2019 May 28;302:19-41
pubmed: 30922946
N Engl J Med. 1998 Dec 10;339(24):1725-33
pubmed: 9867550
J Neurol Neurosurg Psychiatry. 2013 Mar;84(3):244-53
pubmed: 23138770
Dis Markers. 2014;2014:237067
pubmed: 25614710
Cell Physiol Biochem. 2017;44(1):215-228
pubmed: 29131001
Neurosurgery. 2008 May;62(5):E1176-7; discussion E1177
pubmed: 18580791
J Long Term Eff Med Implants. 2000;10(1-2):19-45
pubmed: 10947628
J Biomed Nanotechnol. 2013 Mar;9(3):430-40
pubmed: 23620999
J Cell Mol Med. 2001 Oct-Dec;5(4):378-87
pubmed: 12067471
Ann Biomed Eng. 2016 Feb;44(2):523-35
pubmed: 26139297
J Biomed Mater Res A. 2009 Dec;91(3):878-85
pubmed: 19065570
Circulation. 2003 Mar 11;107(9):1265-70
pubmed: 12628946
Science. 1992 Sep 4;257(5075):1357-63
pubmed: 1529336
Biochem Biophys Res Commun. 2006 Oct 6;348(4):1367-77
pubmed: 16919601
J Am Coll Cardiol. 2010 Nov 30;56(23):1897-907
pubmed: 21109112
Arterioscler Thromb Vasc Biol. 2002 Oct 1;22(10):1617-23
pubmed: 12377739
Adv Drug Deliv Rev. 2006 Jun 3;58(3):377-86
pubmed: 16650911
J Neurointerv Surg. 2018 Dec;10(12):1197-1202
pubmed: 29680819
Pharmacol Ther. 1999 Dec;84(3):413-28
pubmed: 10665838